Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the ...

Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– ...